Article
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Clinical lymphoma, myeloma & leukemia - 1 Aug 2011
Al-Kali Aref, Cortes Jorge, Faderl Stefan, Jones Dan, Abril Caroline, Pierce Sherry, Brandt Mark, Kantarjian Hagop, Ravandi Farhad
Abstract excerpt
BACKGROUND: FMS-like tyrosine kinase 3 (FLT3) is a class III receptor tyrosine kinase involved in hematopoietic progenitor cell development. Mutations of FLT3 have been reported in about a third of patients with acute myeloid leukemia (AML), and inhibitors of FLT3 are of clinical interest. Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.